Gilead Sciences, Inc. $GILD Stock Position Cut by Mubadala Investment Co PJSC

Mubadala Investment Co PJSC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,748 shares of the biopharmaceutical company’s stock after selling 1,160 shares during the period. Gilead Sciences accounts for 0.0% of Mubadala Investment Co PJSC’s holdings, making the stock its 9th biggest position. Mubadala Investment Co PJSC’s holdings in Gilead Sciences were worth $4,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Talon Private Wealth LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $284,000. Bison Wealth LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $215,000. Caisse DE Depot ET Placement DU Quebec lifted its holdings in Gilead Sciences by 149.1% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,025,786 shares of the biopharmaceutical company’s stock valued at $94,752,000 after purchasing an additional 614,059 shares in the last quarter. Finally, Eagle Strategies LLC purchased a new position in Gilead Sciences during the fourth quarter valued at $286,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company’s stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,371,330 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $115.39.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $112.97 on Friday. Gilead Sciences, Inc. has a 12-month low of $77.74 and a 12-month high of $121.83. The stock has a market cap of $140.17 billion, a P/E ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.33. The company has a 50-day moving average price of $113.01 and a 200 day moving average price of $109.59. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.